A quadrivalent vaccine for human papillomavirus.
Cervical cancer is responsible for at least 13,500 deaths a year in the European Union and more than 30 times that worldwide. DNA from a group of human papillomaviruses (HPVs) is found in virtually all cervical carcinoma cells, and these so-called high-risk HPV types are acknowledged to be a necessary cause of this disease. Vaccines that target these HPV types have the potential to dramatically reduce the incidence of cervical carcinoma. Low-risk HPV types cause genital warts, a common sexually transmitted disease, and vaccines that target these HPV types and the high-risk HPV types, are therefore particularly attractive. This review will focus on the potential of a new HPV vaccine that appears to offer protection against the most prevalent high- and low-risk HPV types and their associated diseases.
Brown
Craig
C
Department of Biochemistry, School of Medical Sciences, University of Bristol, UK.
Gaston
Kevin
K
D003218:Condylomata Acuminata / Q000517:prevention & control / Q000628:therapy; D005260:Female; D006801:Humans; D053918:Papillomavirus Vaccines; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control* / Q000628:therapy
D053918:Papillomavirus Vaccines